GENE ONLINE|News &
Opinion
Blog

Kidney Disease
In-Home Kidney Disease Management Company, Monogram, Raises $375 Million
2023-01-13
Vera Therapeutics Eyes Phase 3 For Kidney Disease Candidate Following Positive Data
2023-01-04
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Alnylam Posts Positive Phase 2 Results for its RNAi Nephropathy Drug
2022-08-30
Ocelot’s Rare Kidney Disease Candidate Receives Orphan Drug Designation Going Into Phase 2 Trials
2022-08-23
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
AM-Pharma Partners with Kyowa Kirin in $289m Deal for Kidney Drug
2021-09-09
FDA Approves Cara & Vifor’s CKD-Associated Pruritus Injection
2021-08-26
Venglustat’s Phase 2/3 Trial Failure Pushes Sanofi to Drop Kidney Disease Program
2021-06-02
FDA Approves Second Lupus Nephritis Drug in Two Months
2021-01-25
Chinook Therapeutics Completes Merger with Aduro BioTech Inc.
2020-10-05
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top